Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
2,996
datasets available to search
ShareScore release 0.9.0
Dataset results
2,996 results for “copd”
Oral Prednisolone in Severe Acute Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)
ClinicalTrials.gov study NCT01353235. IPD Sharing: NO. Countries: 1. Publications: 2.
Comparative Effects of IMT Vs EMT Along With AIT in COPD Patients
ClinicalTrials.gov study NCT06308302. IPD Sharing: NO. Countries: 1. Publications: 10.
Reduced COPD Related Utilization of Healthcare Services and Increased Social Activities by Patients Offered a 24/7 Accessible Telehealth Service Based on the Epital Care Model.
ClinicalTrials.gov study NCT06988566. IPD Sharing: YES. Countries: 1. Publications: 7.
Monitoring Coughs for the Early Detection of Worsening COPD
ClinicalTrials.gov study NCT07212439. IPD Sharing: NO. Countries: 1. Publications: 10.
Improving Psychosocial Well-being in COPD Patients in Rehabilitation
ClinicalTrials.gov study NCT03470025. IPD Sharing: NO. Countries: 1. Publications: 22.
Symptom-driven Maintenance and Reliever Treatment to Prevent Exacerbations in COPD
ClinicalTrials.gov study NCT02477397. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Effect of Dexamethasone on Sleep Related Breathing Disturbances in Patients With COPD at Altitude
ClinicalTrials.gov study NCT02450994. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Respiratory Drive Response in COPD Patients During Exercise With Non Invasive Ventilation (NIV).
ClinicalTrials.gov study NCT04597606. IPD Sharing: NO. Countries: 1. Publications: 1.
The Effect On Self-Care and Self-Efficacy of Inhaler Training in COPD
ClinicalTrials.gov study NCT04052906. IPD Sharing: NO. Countries: 1. Publications: 6.
Coping Skills for Patients With Chronic Obstructive Pulmonary Disease (COPD) and Their Caregivers
ClinicalTrials.gov study NCT00736268. IPD Sharing: Not stated. Countries: 1. Publications: 4.
Examining the Genetic Factors That May Cause Chronic Obstructive Pulmonary Disease (COPD)
ClinicalTrials.gov study NCT00608764. IPD Sharing: YES. Countries: 1. Publications: 119.
Sputum-guided Treatment With Comprehensive Care Management in COPD - A Randomized-controlled Trial
ClinicalTrials.gov study NCT04890938. IPD Sharing: NO. Countries: 1. Publications: 3.
Data from: Findings from an exploration of a social network intervention to promote diet quality and health behaviours in older adults with COPD: a feasibility study
Open the record for dataset details and reuse information.
Data from: Assessment of lung function in successfully treated Tuberculosis reveals high burden of ventilatory defects and COPD
Open the record for dataset details and reuse information.
Data from: Sputum microbiota and inflammation at stable state and during exacerbations in a cohort of chronic obstructive pulmonary disease (COPD) patients
Open the record for dataset details and reuse information.
Data from: Comparing microbiota profiles in induced and spontaneous sputum samples in COPD patients
Open the record for dataset details and reuse information.
Exploring the link between airway microbiota and coronary heart disease in COPD patients and controls
Open the record for dataset details and reuse information.
Data from: Vascular disease in COPD: systemic and pulmonary expression of PARC (Pulmonary and Activation-Regulated Chemokine)
Introduction. The role of Pulmonary and Activation-Regulated Chemokine (PARC) in the physiopathology of Chronic Obstructive Pulmonary Disease (COPD) is not fully understood. The aim of the present study is to analyze the expression of PARC in lung tissue and its relationship with the vascular remodeling of the systemic and pulmonary arteries of COPD subjects. Methods. To achieve this objective, protein and gene expression experiments, together with ELISA assays, were performed on the lung tissue, intercostal arteries and serum samples from COPD patients, non-obstructed smokers (NOS) and never-smokers (NS). Results. A total of 57 subjects were included in the analysis (23 COPD, 18 NOS and 16 NS). In the comparisons between groups, a significantly increased lung protein expression of PARC was observed in the COPD group compared to the NOS group (1.96±0.22 vs. 1.29±0.27, P-adjusted=0.038). PARC was located predominantly in the smooth muscle cells of the remodeled pulmonary muscular arteries and the macrophage-rich area of the alveolar parenchyma. No differences were detected in PARC gene expression analyses. The protein content of PARC in the intercostal arteries were similar between groups, though little remodeling was observed in these arteries. Circulating levels of PARC were numerically higher in patients with COPD compared to NOS and NS. Conclusion. The results of the present study suggest an increased lung protein expression of PARC in COPD subjects. This protein was mainly localized in the smooth muscle cells of the pulmonary muscular arteries and was associated with the severity of intimal thickening, indicating its possible role in this remodeling process.
Data from: Effectiveness of diagnostic screening tests in mass screening for COPD using a cooperative regional system in a region with heavy air pollution: a cross-sectional study
Objective: This research aimed to evaluate the effectiveness of a cooperative health care model for early detection and diagnosis of chronic obstructive pulmonary disease (COPD), in Omuta Japan. Methods: This was a cross-sectional observational study. We performed diagnosis of COPD at four public health centres in Omuta, Japan from March 2015 to March 2016, by adding screening for COPD at the time of routine medical evaluations. All patients over 50 years were eligible to participate. Of a total of 397 eligible patients, 293 agreed to take part in the study. Results: The estimated prevalence of COPD in Omuta was 10% among subjects over 40 years and was 17% among smokers. Out of those who were screened, over half had questionnaire scores over the cut-off of 17 points and decreased FEV1/FVC%, indicating COPD (p>0.05). Thirty subjects with suspected COPD were given a referral for further investigation at a local central hospital, but only six underwent further medical examinations. Conclusion: The combination of COPD questionnaire and medical exam was effective as a COPD screening tool. Future research should investigate behavioural interventions for smoking cessation that can be offered in a cooperative model, as well as for improving participation in COPD screening and for encouraging early presentation for treatment in those suspected of having COPD.
Data from: Efficacy and safety of four weeks' treatment with combined fluticasone furoate/vilanterol in a single inhaler given once daily in COPD: a placebo-controlled randomised trial
BACKGROUND: Fluticasone furoate/vilanterol (FF/VI) is a novel once-daily (OD) inhaled corticosteroid/long-acting β2 agonist combination in development for chronic obstructive pulmonary disease (COPD) and asthma. TRIAL DESIGN: A multicentre, randomised, double-blind, parallel-group, placebo-controlled study. METHODS: Participants were patients with moderate-to-severe COPD treated with placebo or FF/VI 400/25 μg OD for 4 weeks. Study objectives were to assess the safety and efficacy of FF/VI 400/25 μg OD administered for 4 weeks via a novel dry powder inhaler. Co-primary end points were change from baseline in weighted mean (wm) heart rate 0–4 h postdose at day 28 and the incidence of adverse events (AEs). Secondary end points included change from baseline in trough forced expiratory volume in one second (FEV1) (23–24 h postdose; day 29) and wm FEV1 (0–4 h postdose; day 28). Patients were randomised to receive FF/VI 400/25 μg or placebo in a 2:1 ratio; all patients and investigators were blinded to active or placebo treatment. RESULTS: 60 patients (mean age 64 years) were randomised (FF/VI: n=40; placebo: n=20), and all contributed data to the analysis. Mean screening post-bronchodilator FEV1 per cent predicted was comparable between groups (FF/VI: 58.5%; placebo: 60.1%). The wm heart rate 0–4 h postdose was similar between groups (difference: 0.6 beats per minute; 95% CI −3.9 to 5.1). More on-treatment AEs were reported in the FF/VI group (68%) compared with the placebo group (50%). The most common drug-related AEs in the FF/VI group were oral candidiasis (8%) and dysphonia (5%). There were no clinically relevant effects on laboratory values, including glucose and potassium, or on vital signs or ECGs/Holters. The FF/VI group had statistically greater improvements compared with placebo in trough FEV1 (mean difference 183 ml) and 0–4 h postdose wm FEV1 (mean difference 236 ml). CONCLUSION: FF/VI has a good safety and tolerability profile and improves lung function compared with placebo in patients with COPD.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.